Chufan Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chufan Luo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Guihua Lu
Department of Cardiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510800, China
2 shared publications - Xiuren Gao
Department of Cardiology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
2 shared publications - Chenggui Xu
Department of Cardiology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China; Key Laboratory on Assisted Circulation, Ministry of Health, Guangzhou 510080, China
1 shared publication - Chenyao Sun
Beijing University of Chinese Medicine, Beijing, China
1 shared publication Hua Duan
Department of China-Japan Friendship Hospital, Beijing University of Chinese Medicine, Beijing, China
1 shared publication- Huijuan Cui
Department of Integrative Oncology, China-Japan Friendship Hospital
1 shared publication
Latest Publications
- Open Access
- 17 February 2020
- Published by Atlantis Press SARL
- p. 242-249
Measuring of Inequality Using the Household Electricity Meter Reading Data in Urban China
- 17 February 2020
- Published by Atlantis Press SARL
- p. 242-249
Open AccessMeasuring of Inequality Using the Household Electricity Meter Reading Data in Urban China
- Open Access
- 1 April 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 2303-2309
Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report
Epidermal growth factor receptor-tyrosine kinase inhibitors have improved progression-free survival and overall survival in non-small-cell lung cancer (NSCLC) patients with sensitive mutations. However, response of uncommon mutation to epidermal growth factor receptor-tyrosine kinase inhibitors is still unclear. S768I is one of the uncommon mutations. A female patient with advanced NSCLC with a single S768I mutation achieved effectiveness from afatinib after showing no response to gefitinib. The patient had progression-free survival after taking afatinib for 6 months, and her follow-up is continuing. It suggests that afatinib may be a more effective treatment for NSCLC patients with a single S768I mutation, compared to first-generation tyrosine kinase inhibitors.
- 1 April 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 2303-2309
Open AccessEffectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report
Epidermal growth factor receptor-tyrosine kinase inhibitors have improved progression-free survival and overall survival in non-small-cell lung cancer (NSCLC) patients with sensitive mutations. However, response of uncommon mutation to epidermal growth factor receptor-tyrosine kinase inhibitors is still unclear. S768I is one of the uncommon mutations. A female patient with advanced NSCLC with a single S768I mutation achieved effectiveness from afatinib after showing no response to gefitinib. The patient had progression-free survival after taking afatinib for 6 months, and her follow-up is continuing. It suggests that afatinib may be a more effective treatment for NSCLC patients with a single S768I mutation, compared to first-generation tyrosine kinase inhibitors.
- Open Access
- 31 December 2016
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 35 (2)
Hydrochlorothiazide modulates ischemic heart failure‐induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats
Summary: Aims: Our previous study indicates that hydrochlorothiazide inhibits transforming growth factor (TGF)‐β/Smad signaling pathway, improves cardiac function and reduces fibrosis. We determined whether these effects were common among the diuretics and whether angiotensin II receptor type 1 (AT1) signaling pathway played a role in these effects.Methods: Heart failure was produced by ligating the left anterior descending coronary artery in adult male Sprague Dawley rats. Two weeks after the ligation, 70 rats were randomly divided into five groups: sham‐operated group, control group, valsartan group (80 mg/kg/d), hydrochlorothiazide group (12.5 mg/kg/d) and furosemide group (20 mg/kg/d). In addition, neonatal rat ventricular fibroblasts were treated with angiotensin II.Results: After eight‐week drug treatment, hydrochlorothiazide group and valsartan group but not furosemide group had improved cardiac function (ejection fraction was 49.4±2.1%, 49.5±1.8% and 39.9±1.9%, respectively, compared with 40.1±2.2% in control group), reduced cardiac interstitial fibrosis and collagen volume fraction (9.7±1.2%, 10.0±1.3% and 14.1±0.8%, respectively, compared with 15.9±1.1% in control group), and decreased expression of AT1, TGF‐β and Smad2 in the cardiac tissues. In addition, hydrochlorothiazide reduced plasma angiotensin II and aldosterone levels. Furthermore, hydrochlorothiazide inhibited angiotensin II‐induced TGF‐β1 and Smad2 protein expression in the neonatal rat ventricular fibroblasts.Conclusions: Our study indicates that the cardiac function and remodeling improvement after ischemic heart failure may not be common among the diuretics. Hydrochlorothiazide may reduce the left ventricular wall stress and angiotensin II signaling pathway to provide these beneficial effects.
- 31 December 2016
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 35 (2)
Open AccessHydrochlorothiazide modulates ischemic heart failure‐induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats
Summary: Aims: Our previous study indicates that hydrochlorothiazide inhibits transforming growth factor (TGF)‐β/Smad signaling pathway, improves cardiac function and reduces fibrosis. We determined whether these effects were common among the diuretics and whether angiotensin II receptor type 1 (AT1) signaling pathway played a role in these effects.Methods: Heart failure was produced by ligating the left anterior descending coronary artery in adult male Sprague Dawley rats. Two weeks after the ligation, 70 rats were randomly divided into five groups: sham‐operated group, control group, valsartan group (80 mg/kg/d), hydrochlorothiazide group (12.5 mg/kg/d) and furosemide group (20 mg/kg/d). In addition, neonatal rat ventricular fibroblasts were treated with angiotensin II.Results: After eight‐week drug treatment, hydrochlorothiazide group and valsartan group but not furosemide group had improved cardiac function (ejection fraction was 49.4±2.1%, 49.5±1.8% and 39.9±1.9%, respectively, compared with 40.1±2.2% in control group), reduced cardiac interstitial fibrosis and collagen volume fraction (9.7±1.2%, 10.0±1.3% and 14.1±0.8%, respectively, compared with 15.9±1.1% in control group), and decreased expression of AT1, TGF‐β and Smad2 in the cardiac tissues. In addition, hydrochlorothiazide reduced plasma angiotensin II and aldosterone levels. Furthermore, hydrochlorothiazide inhibited angiotensin II‐induced TGF‐β1 and Smad2 protein expression in the neonatal rat ventricular fibroblasts.Conclusions: Our study indicates that the cardiac function and remodeling improvement after ischemic heart failure may not be common among the diuretics. Hydrochlorothiazide may reduce the left ventricular wall stress and angiotensin II signaling pathway to provide these beneficial effects.
- Open Access
- 20 May 2015
- Published by Springer Nature in Biological Trace Element Research
- Vol. 168 (2) , 411-420
Zinc Regulates Lipid Metabolism and MMPs Expression in Lipid Disturbance Rabbits
Lipid disturbance induced by high-fat diet is a worldwide problem, and it can induce inflammation and oxidative stress in vivo. Zinc is considered as an antioxidant, anti-inflammatory agent. Since matrix metalloprotease 2 (MMP2) and matrix metalloprotease 9 (MMP9)’s expressions are changed under many pathological conditions, we would like to know how zinc affects lipid metabolism and MMP2, MMP9’s expressions in the lipid disturbance rabbits. Twenty-four male New Zealand white rabbits were randomly divided into four groups. Each group had six rabbits, and they were fed with regular diet, high-fat diet, high-fat diet + zinc, and regular diet + zinc separately for 12 weeks. High-fat diet induced lipid disturbance significantly which raised the level of aspartate aminotransferase (p < 0.01) and alanine transaminase (p < 0.05) in the high-fat diet group, but zinc supplement reversed this phenomenon (p < 0.05). Zinc did not reduce total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) (p > 0.05), but it lowered triglyceride (TG) and raised high-density lipoprotein cholesterol (HDL-C) (p < 0.01). Zinc also reduced high-sensitivity C-reactive protein (hs-CRP) (p < 0.01) and interleukin-6 (IL-6)’s expressions (p < 0.05). Zinc reduced the epicardial adipose tissue and alleviated the hepatic steatosis. Zinc suppressed MMP2 and MMP9’s expressions in vivo, but it did not alleviate the aorta fatty streak’s severity in the lipid disturbance rabbits. Zinc protected the liver, reduced TG, hs-CRP, and IL-6 and raised HDL-C in the lipid disturbance rabbits. Zinc suppressed MMP2 and MMP9’s expressions in vivo, but it did not alleviate the severity of aorta fatty streak induced by the high-fat diet.
- 20 May 2015
- Published by Springer Nature in Biological Trace Element Research
- Vol. 168 (2) , 411-420
Open AccessZinc Regulates Lipid Metabolism and MMPs Expression in Lipid Disturbance Rabbits
Lipid disturbance induced by high-fat diet is a worldwide problem, and it can induce inflammation and oxidative stress in vivo. Zinc is considered as an antioxidant, anti-inflammatory agent. Since matrix metalloprotease 2 (MMP2) and matrix metalloprotease 9 (MMP9)’s expressions are changed under many pathological conditions, we would like to know how zinc affects lipid metabolism and MMP2, MMP9’s expressions in the lipid disturbance rabbits. Twenty-four male New Zealand white rabbits were randomly divided into four groups. Each group had six rabbits, and they were fed with regular diet, high-fat diet, high-fat diet + zinc, and regular diet + zinc separately for 12 weeks. High-fat diet induced lipid disturbance significantly which raised the level of aspartate aminotransferase (p < 0.01) and alanine transaminase (p < 0.05) in the high-fat diet group, but zinc supplement reversed this phenomenon (p < 0.05). Zinc did not reduce total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) (p > 0.05), but it lowered triglyceride (TG) and raised high-density lipoprotein cholesterol (HDL-C) (p < 0.01). Zinc also reduced high-sensitivity C-reactive protein (hs-CRP) (p < 0.01) and interleukin-6 (IL-6)’s expressions (p < 0.05). Zinc reduced the epicardial adipose tissue and alleviated the hepatic steatosis. Zinc suppressed MMP2 and MMP9’s expressions in vivo, but it did not alleviate the aorta fatty streak’s severity in the lipid disturbance rabbits. Zinc protected the liver, reduced TG, hs-CRP, and IL-6 and raised HDL-C in the lipid disturbance rabbits. Zinc suppressed MMP2 and MMP9’s expressions in vivo, but it did not alleviate the severity of aorta fatty streak induced by the high-fat diet.